Business Description
Design Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US25056L1035
Description
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 100.74 | |||||
| Equity-to-Asset | 0.97 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.04 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -107.6 | |||||
| 3-Year EPS without NRI Growth Rate | -97.7 | |||||
| 3-Year FCF Growth Rate | -86.5 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 57.58 | |||||
| 9-Day RSI | 54.06 | |||||
| 14-Day RSI | 53.58 | |||||
| 6-1 Month Momentum % | 40.52 | |||||
| 12-1 Month Momentum % | 151.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 34.61 | |||||
| Quick Ratio | 34.61 | |||||
| Cash Ratio | 34.19 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.6 | |||||
| Shareholder Yield % | 0.2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -17.75 | |||||
| ROA % | -17.07 | |||||
| ROIC % | -696.5 | |||||
| ROC (Joel Greenblatt) % | -1365.35 | |||||
| ROCE % | -22.41 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.35 | |||||
| Price-to-Tangible-Book | 1.35 | |||||
| EV-to-EBIT | -1.45 | |||||
| EV-to-EBITDA | -1.46 | |||||
| EV-to-FCF | -1.9 | |||||
| Price-to-Net-Current-Asset-Value | 1.37 | |||||
| Price-to-Net-Cash | 1.39 | |||||
| Earnings Yield (Greenblatt) % | -68.97 | |||||
| FCF Yield % | -13.66 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:DSGN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Design Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.85 | ||
| Beta | 2.08 | ||
| Volatility % | 75.61 | ||
| 14-Day RSI | 53.58 | ||
| 14-Day ATR ($) | 0.460339 | ||
| 20-Day SMA ($) | 5.9065 | ||
| 12-1 Month Momentum % | 151.63 | ||
| 52-Week Range ($) | 2.245 - 7.77 | ||
| Shares Outstanding (Mil) | 56.62 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Design Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Design Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Design Therapeutics Inc Frequently Asked Questions
What is Design Therapeutics Inc(DSGN)'s stock price today?
The current price of DSGN is $6.00. The 52 week high of DSGN is $7.77 and 52 week low is $2.25.
When is next earnings date of Design Therapeutics Inc(DSGN)?
The next earnings date of Design Therapeutics Inc(DSGN) is 2025-03-19 Est..
Does Design Therapeutics Inc(DSGN) pay dividends? If so, how much?
Design Therapeutics Inc(DSGN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers